This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Updated from 2:08 p.m. EDT

Geron (GERN - Get Report) was the best health care performer of Thursday's sluggish session, following positive news out of a recently study.

Shares jumped 15.1% after Geron said that its scientists have seen progress in using embryonic stem cells as an effective treatment for type 1 diabetes. Recently, Geron closed up $1.24o $9.48

Despite the advance in its stock, Geron was unable to support the Nasdaq Biotechnology Index, which slumped 0.7. Among its other components, Genzyme (GENZ) lost 3.2% and Amgen (AMGN - Get Report) shed 1.2%.

Angiotech Pharmaceuticals (ANPI) was up 5.2% after a regulatory approval for a wound closure product. The company's Quill SRS received European approval and is expected to launch there at midyear. Recently, Angio closed up 34 cents at $6.89.

Onyx Pharmaceuticals (ONXX) was another winner, courtesy of an upgrade from Friedman Billings. The firm raised its rating for Onyx to market perform from underperform, while nearly doubling its stock price target to $30 from $17.

An analyst with Friedman said it will take years for Pfizer (PFE - Get Report) to come up with a drug that can compete with Onyx's a liver cancer treatment, Nexavar. Recently, Onyx added 57 cents, or 1.8%, to $31.87. Pfizer was down by 4 cents earlier in the day but closed up 4 cents at $27.36.

Also among winners, Avanir Pharmaceutical (AVNR) was higher by 21.8%, Dendreon (DNDN) climbed 6.5%, and CV Therapeutics (CVTX) was up 6.2%.

On the losing side, medical device makers were having a rough session. Among individual names, Boston Scientific (BSX) fell 2.3%, Medtronic (MDT) slumped 1.6%, and St. Jude Medical (STJ) was off 1.2%.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
ONXX $0.00 0.00%
AMGN $151.78 -2.64%
DNDN $0.06 -6.02%
GERN $3.03 -6.19%
PFE $32.22 -1.35%


Chart of I:DJI
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASDAQ 4,776.5080 -51.8170 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs